Immunogenicity in Clinical Practice and Drug Development: When is it Significant?

Creator(s)

Valentina Shakhnovich, Children's Mercy HospitalFollow
Bernd Meibohm, University of Tennessee Health Science Center
Amy Rosenberg, Food and Drug Administration
Andrzej M. Kierzek, Certara, United Kingdom
Rachel Hasenkamp, Children's Mercy HospitalFollow
Ryan S. Funk, University of Kansas
Craig J. Thalhauser, Bristol-Myers Squibb
Piet H. van der Graaf, Certara, United Kingdom
Yow Ming C. Wang, Food and Drug Administration
Lora Hamuro, Bristol-Myers Squibb

Document Type

Article

Publication Date

3-2020

Identifier

10.1111/cts.12717; PMCID: PMC7070797

Journal Title

Clinical and Translational Science

Volume

13

Issue

2

First Page

219

Last Page

223

Comments

Grant support

• KL2 TR002367/TR/NCATS NIH HHS/United States
• P20 GM130423/GM/NIGMS NIH HHS/United States
• L40 TR000598/TR/NCATS NIH HHS/United States

Recommended Citation

Shakhnovich V, Meibohm B, Rosenberg A, et al. Immunogenicity in Clinical Practice and Drug Development: When is it Significant?. Clin Transl Sci. 2020;13(2):219-223. doi:10.1111/cts.12717